Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MAX-3
- Development stage
- Phase 1
- Lead developer
- Guangzhou Zaiji Medical Technology
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
MAX-3 is a small molecule Janus kinase (JAK) inhibitor developed by Guangzhou Zaiji Medical Technology (also known as Maxinovel). It is designed to treat autoimmune and inflammatory diseases by blocking the JAK-STAT signaling pathway, which is critical for the production of pro-inflammatory cytokines. The drug is currently being evaluated in Phase 1 clinical trials for indications including alopecia areata and atopic dermatitis. By inhibiting the intracellular enzymes that mediate signaling from cytokine receptors, MAX-3 aims to modulate the immune response and reduce the inflammatory processes underlying these skin conditions.
- Other names
- MAX-3MAX3MAX 3
02
Targets
TYK2 (Tyrosine kinase 2)
Beyond the preview
Go deeper on MAX-3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MAX-3.